04.01.20
Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO) which specializes in immediate and modified release oral solids and packaging, has appointed Lonnie Barish as vice president of business development and marketing.
Adding more than 25 years of pharmaceutical, biotech, and medical device experience to the team, Barish will offer local support to new and existing clients in North America whilst helping to boost the growth of Bora’s North American business.
Lonnie Barish
“We are truly honored to add Lonnie to our growing team in North America,” said Bobby Sheng, chief executive officer, Bora Pharmaceuticals. “Lonnie has been a senior leader at some of the most dynamic contract service organizations in our industry. He will contribute significant business development and commercial experience alongside a deep understanding of the needs of our pharmaceutical industry customers.
“As more customers continue to outsource their most challenging oral solid drug products to us, there is a greater need than ever for our extended release and solvent processing capabilities. Lonnie will help us to meet this demand and ensure we are reaching those pharmaceutical companies that would benefit from our skilled team and services.”
Headquartered in Zhunan, Taiwan, Bora recently confirmed plans to acquire GSK’s Mississauga, Canada facility by the end of 2020. The deal, which will considerably increase Bora’s size, capacity, and capabilities to include semi solids and liquids, will see the company commit to retaining approximately 400 GSK staff and continue to produce GSK products for over 100 markets for a minimum of five years.
Mr. Barish, who has held leadership roles at Cytovance Biologics, WellSpring, Nuvisan and AAIPharma, is the first of a number of planned key appointments as the company looks to expand its business development team across the continent.
Across its two sites in Taiwan, Bora offers a broad range of technologies to its global customer-base from development to manufacturing, packaging, distribution, technical transfer, stability studies, and product life cycle management.
Adding more than 25 years of pharmaceutical, biotech, and medical device experience to the team, Barish will offer local support to new and existing clients in North America whilst helping to boost the growth of Bora’s North American business.
Lonnie Barish
“As more customers continue to outsource their most challenging oral solid drug products to us, there is a greater need than ever for our extended release and solvent processing capabilities. Lonnie will help us to meet this demand and ensure we are reaching those pharmaceutical companies that would benefit from our skilled team and services.”
Headquartered in Zhunan, Taiwan, Bora recently confirmed plans to acquire GSK’s Mississauga, Canada facility by the end of 2020. The deal, which will considerably increase Bora’s size, capacity, and capabilities to include semi solids and liquids, will see the company commit to retaining approximately 400 GSK staff and continue to produce GSK products for over 100 markets for a minimum of five years.
Mr. Barish, who has held leadership roles at Cytovance Biologics, WellSpring, Nuvisan and AAIPharma, is the first of a number of planned key appointments as the company looks to expand its business development team across the continent.
Across its two sites in Taiwan, Bora offers a broad range of technologies to its global customer-base from development to manufacturing, packaging, distribution, technical transfer, stability studies, and product life cycle management.
